Not Your Typical Fruit Snack: Welch's® Juicefuls® Fusions™ Just Dropped
PARK RIDGE, N.J., July 7, 2025 /PRNewswire/ — Welch's® Fruit Snacks, America's #1 Fruit Snacks Brand, has announced the launch of Welch's® Juicefuls® Fusions™, a transformational innovation in Juicy Filled Fruit Snacks.
Welch's® Juicefuls® Fusions™ are the first-ever soft and delicious fruit snacks with one flavor on the chewy outside fused with another on the juicy bursting center. Welch's® Juicefuls® Fusions™ are available in mouth-watering double-flavor combinations including Watermelon & Lemon, Green Apple & Peach, and Blueberry & Raspberry. Every seriously snackable bite delivers '2 in 1 Juicy Fun' and an unexpected, multi-sensory experience for adventurous tastebuds only.
'For generations, we have been delivering one of the most beloved snacks and reimagining what fruit snacks made with Real, Whole Fruit can be,' said Jason Levine, Chief Marketing Officer at PIM Brands Inc., makers of Welch's® Fruit Snacks. 'Welch's® Juicefuls® Fusions™ are a new kind of snack, made for young adults who grew up with us and now want something as modern, flavorful, and dynamic as they are. We can't wait for our fans to try them and fall in love all over again.'
Three craveable Welch's® Juicefuls® Fusions™ are included in every dynamically colorful pack and made with only Natural Flavors, Colors from Natural Sources, and an Excellent Source of Vitamins A, C, and E. Like all Welch's® Fruit Snacks, Juicefuls® Fusions™ are gluten free and peanut free. Welch's® Juicefuls® Fusions™ are currently available in a variety of pack sizes with more size and flavor combinations coming soon:
4oz peg bags available nationwide at select convenience retailers
20 count boxes of 0.8oz pouches available at Walmart and Target, coming soon to other leading retailers nationwide this summer
50 count boxes of 0.8oz pouches available exclusively on Amazon
Follow along on social media for more innovative and exciting updates in the coming months: @WelchsFruitSnck on Instagram and @WelchsFruitSnacks on TikTok. For more information on the brand, please visit www.welchsfruitsnacks.com.
ABOUT PIM BRANDS INC.:PIM Brands, Inc. is the world's largest maker of Real Fruit Snacks and related treats and is also one of the world's largest makers of chocolate and non-chocolate confections. Currently ranked as #26 on Candy Industry Magazine's 'Global Top 100' confectionery companies in the world and #10 in North America by Candy Industry Magazine, PIM Brands, Inc. is also ranked by Crain's Business as one of the New York Metro Area's 100 largest privately owned companies, and by NJBIZ as one of the State's largest privately held employers.
PIM Brands, Inc. has been named as one of the fastest-growing Consumer Packaged Goods (CPG) companies in the U.S.A. by Circana (formerly Information Resources, Inc.) and The Boston Consulting Group (BCG) six times since 2012.
Millions of times each day all across the world, consumers enjoy PIM's vast array of loved brands including Welch's® Fruit Snacks, Welch's® Juicefuls® Juicy Fruit Snacks, Welch's® Fruit 'n Yogurt™ Snacks, Welch's® Juicefuls® Fusions™, Welch's® Fruit Rolls, Welch's® Zero Sugar Fruity Bites, Welch's® Fruitfuls™ Fruit Strips, Sun-Maid® Chocolate Raisins, Toggi® Fine European Chocolate Wafers, Tuxedos® Chocolate Almonds, Original Gummi FunMix®, Sour Jacks® Sour Candies, Slice™ Fruit On the-Go™ Fruit Bars, Nuclear SQWorms® Sour Gummi Worms and many more.
PIM's subsidiaries and affiliates include PIM Brands LLC, PIM Brands Canada, PIM Brands Mexico S DE RL DE CV, PIM Brands Iberica, SL, PIM Brands UK, Ltd, PIM Brands Hindustani Private Limited, PIM Global Holdings LLC, PIM Consumer Health LLC, Pharma In Motion LLC and Farmer's Choice Food Brands.
About Welch's:Founded more than 150 years ago and headquartered in Massachusetts, Welch's is an iconic and leading fruit-based food, beverage, and agricultural cooperative owned by 650 family farms across the United States. Our purpose of nourishing through the goodness of fruit is at the core of everything we do and unites our growers and employees in our quest to be the best. We are on a mission to sustainably deliver flavorful moments to consumers everywhere with our delicious real fruit juices, refreshingly sweet sparkling juices, and family-favorite fruit spreads, jams, and jellies.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Malaysian Reserve
13 hours ago
- Malaysian Reserve
OSR Holdings to Host Virtual Investor Event Providing Key Corporate Updates and Strategic Direction on August 6, 2025
BELLEVUE, Wash., Aug. 1, 2025 /PRNewswire/ — OSR Holdings, Inc. (NASDAQ: OSRH), a global healthcare company advancing biomedical innovations to improve health and wellness worldwide, today announced that it will host a Virtual Investor Event on Wednesday, August 6, 2025 at 8:00 a.m. Eastern Time (2:00 p.m. Central European Summer Time / 9:00 p.m. Korea Standard Time). The event will provide shareholders and prospective investors with a detailed update of the Company's strategic direction, subsidiary performance, capital allocation, and pipeline R&D. Senior members of the OSRH executive team will be presenting. Event Details Date: Wednesday, August 6, 2025Time: 8:00 a.m. ET / 2:00 p.m. CEST / 9:00 p.m. KSTLocation: Virtual (livestream access)Registration: Opens Monday, August 4 at Available after the event on the OSR Holdings Investor Relations website. Agenda Highlights Corporate overview and strategic vision Subsidiary and R&D pipeline updates: Vaximm: Tailored, Antigen-specific in vivo T-cell Immunotherapies Darnatein: DRT101 – a potent DMOAD candidate Woori IO acquisition: The opportunity for noninvasive CGM Equity Line of Credit (ELOC) financing strategy Blockchain & Tokenization strategy Live Q&A with management Vaximm: Tailored, Antigen-specific in vivo T-cell Immunotherapies Darnatein: DRT101 – a potent DMOAD candidate Woori IO acquisition: The opportunity for noninvasive CGM 'This event is a timely opportunity to engage with our shareholders and the broader investment community as we move into a transformative stage in OSR's growth,' said Peter Hwang, CEO of OSRH. 'We look forward to showcasing the strength of our platform, the progress we've made, and the catalysts ahead. We are committed to transparency, disciplined execution, and delivering meaningful value to all stakeholders in the coming months.'Featured Speakers: Mr. Peter Hwang – Chief Executive Officer Dr. Constance Höfer – Chief Scientific Officer Mr. Tim Smith – Global Investor Relations About OSR Holdings, Inc. OSR Holdings, Inc. (NASDAQ: OSRH) is a global healthcare holding company dedicated to advancing biomedical innovation approaches to health and wellness to support global health outcomes. Through its subsidiaries, OSRH is engaged in immuno‑oncology, regenerative biologics, and medical device distribution. OSRH's vision is to acquire and operate a portfolio of innovative healthcare and wellness companies, improving patient care through cutting‑edge research and development. For more information, visit
Malaysian Reserve
13 hours ago
- Malaysian Reserve
MiRus Receives New Technology Add-on Payment (NTAP) for EUROPA™ Posterior Cervical Fusion System
ATLANTA, Aug. 1, 2025 /PRNewswire/ — MiRus has received New Technology Add-on Payment (NTAP) from the Centers for Medicare and Medicaid Services (CMS) for the EUROPA® Posterior Cervical System, based on it's proprietary rhenium alloys, for treatment of the cervical and upper thoracic spine. The EUROPA® PCF system is built around a 2.9 mm MoRe rod which is much smaller than current commercial systems. The lower diameter rod allows low-profile pedicle screw tulips leading to less invasive surgery and less hardware prominence in smaller patients. Although lower diameter, MoRe rods provide a superior level of rigidity, strength, and fatigue resistance which reduces the risk of spine rod fractures compared to current systems. The EUROPA® PCF System was awarded Breakthrough Device Designation by the FDA. 'I have used the 4.5mm MoRe rod TL system for complex cases and have had good results,' stated Han Jo Kim MD, Professor of Orthopedic Surgery at the Hospital for Special Surgery, New York 'There is tremendous potential in what this proprietary alloy (MoRe) can accomplish in spine surgery, offering implants that are lower profile, more durable and stronger.' 'We are pleased that CMS has recognized the EUROPA® PCF System as the superior option for treating the cervical and upper thoracic spine, enabling hospitals to receive reimbursement through the NTAP program and ensuring Medicare patients have access to this breakthrough technology,' commented Mahesh Krishnan, Chief Commercial Officer. 'Currently the rates of spine implant failures and revision surgeries for patients remain unacceptably high,' commented Jordan Bauman, VP of Regulatory and Quality. 'with EUROPA® PCF, spine surgeons will be able to provide durable and less invasive surgery for their cervicothoracic patients. This is another step forward in our mission to provide less invasive and more durable devices across a broad spectrum of disease states.' About MiRus, is a life sciences company headquartered in Atlanta, Georgia that has developed and is commercializing proprietary novel biomaterials and implants that are transforming medicine by making surgeries less invasive and implants safer and more durable. Statements made in this press release that look forward in time or that express beliefs, expectations or hopes regarding future occurrences or anticipated outcomes are forward-looking statements. A number of risks and uncertainties such as risks associated with product development and commercialization efforts, expected timing or results of any clinical trials, ultimate clinical outcome and perceived or actual advantages of the Company's products, market and physician acceptance of the products, intellectual property protection, and competitive offerings could cause actual events to adversely differ from the expectations indicated in these forward looking statements. The EUROPA® Posterior Cervical System is not FDA approved. * MiRus® , EUROPA®, MoRe® are all trademarks of MiRus, LLC. Contact:Pam CowartVP of Clinical Affairspcowart@
Malaysian Reserve
13 hours ago
- Malaysian Reserve
Elixir MD Launches Australia & New Zealand Subsidiary in Exclusive Partnership with High Tech Medical Pty. Ltd.
IRVINE, Calif. and QUEENSLAND, Australia, Aug. 1, 2025 /PRNewswire/ — ELIXIR MD, Inc., a pioneer in advanced medical technology and proprietary treatment protocols for plastic surgery, today announced the formation of its wholly owned subsidiary in Australia and New Zealand, alongside an exclusive partnership with High Tech Medical Pty Ltd. to launch the ELIXIR MD™ device across the region. Ewan Mohammed, CEO of ELIXIR MD, Inc., stated:'We're proud to join forces with High Tech Medical—Australia and New Zealand's leading medical technology partner—to bring the ELIXIR MD™ device to facial surgery patients across one of the world's fastest-growing cosmetic markets. With more than 25 years of proven commitment to clinical excellence, High Tech Medical brings deep market insight and trusted relationships throughout the aesthetic medical community. Their long-standing success in introducing advanced technologies to Australians and New Zealanders makes them the ideal partner for ELIXIR MD, Inc.' Matt Moncrieff, Managing Director of High-Tech Medical Pty Ltd., added:'High Tech Medical is proud to work exclusively with ELIXIR MD, Inc., Ewan and the entire team have demonstrated a clear commitment to innovation and to reshaping the perioperative care model in plastic surgery. The ELIXIR MD™ device and its proprietary treatment protocols represent a new gold standard in post-surgical recovery by significantly reducing patient downtime and improving outcomes.' Australia and New Zealand: A Rising Market for Surgical Innovation Australian cosmetic surgery market reached approximately $1.8B in 2024, with expected growth to $3.9B by 2033, reflecting a CAGR of ~9.3% (IMARC Group, Rentech Digital). Facial cosmetic surgery—the category where ELIXIR MD™ is uniquely focused—is the fastest-growing segment of the cosmetic surgery market in Australia, with a projected CAGR of approximately 14.1% through 2030 (Grand View Research). Demand for face and eyelid surgeries (e.g. blepharoplasty, facelifts) is rising sharply in Australia and New Zealand, in key part driven by post-weight loss volume depletion and rejuvenation surgery (Daily Telegraph). About High Tech Medical Pty in 1999, High Tech Medical is one of the most respected providers of specialist aesthetic medical devices across Australia and New Zealand. With over two decades of leadership, the company has introduced breakthrough technologies that support minimally invasive treatments, reduce patient risk and downtime, and improve clinical outcomes. High Tech Medical is known for its consultative approach—helping practitioners select and integrate complex, high-performance systems into their practices with confidence. About ELIXIR MD, in Irvine, California, ELIXIR MD, Inc. is a medical technology company redefining recovery in plastic surgery through non-invasive, perioperative innovations. Now operating in 18 markets—including a wholly owned subsidiary in Australia and New Zealand—our FDA-cleared ELIXIR MD™ technology is built to support faster healing and better outcomes for surgeons and their patients worldwide.
